To Switch or Not to Switch: Biosimilars in Rheumatology

In this episode, we get further insight into the current state of biosimilars development and adoption in the United States vs other countries, interchangeability among adult and pediatric patients with rheumatologic conditions, nonmedical switching to biosimilars, and an overview of its potential cost benefits for the US healthcare system.

Next post in Practice Management